Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Savara, Inc. - Common Stock (NQ: SVRA ) 3.050 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2025 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 42 Open 3.050 Bid (Size) 2.950 (1) Ask (Size) 3.120 (50) Prev. Close 3.050 Today's Range 3.050 - 3.050 52wk Range 2.815 - 5.700 Shares Outstanding 114,066,080 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Savara Announces New Employment Inducement Grant December 23, 2024 From Savara Inc. Via Business Wire Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) December 18, 2024 From Savara Inc. Via Business Wire Performance YTD -0.65% -0.65% 1 Month -14.33% -14.33% 3 Month -18.45% -18.45% 6 Month -33.26% -33.26% 1 Year -32.37% -32.37% More News Read More Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference December 17, 2024 From Savara Inc. Via Business Wire SVRA Stock Earnings: Savara Misses EPS for Q2 2024 August 12, 2024 Via InvestorPlace Savara Announces New Employment Inducement Grant November 22, 2024 From Savara Inc. Via Business Wire Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 November 22, 2024 From Savara Inc. Via Business Wire Savara Announces Participation in Upcoming Healthcare Conferences November 13, 2024 From Savara Inc. Via Business Wire Savara Reports Third Quarter 2024 Financial Results and Provides Business Update November 12, 2024 From Savara Inc. Via Business Wire Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference November 04, 2024 From Savara Inc. Via Business Wire Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV October 22, 2024 From Savara Inc. Via Business Wire Savara Announces New Employment Inducement Grant October 18, 2024 From Savara Inc. Via Business Wire Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting October 01, 2024 From Savara Inc. Via Business Wire Savara Announces New Employment Inducement Grant September 27, 2024 From Savara Inc. Via Business Wire Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) September 27, 2024 From Savara Inc. Via Business Wire Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately September 24, 2024 From Savara Inc. Via Business Wire Savara to Host Analyst and Investor Webinar on September 30, 2024 September 23, 2024 From Savara Inc. Via Business Wire Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket September 09, 2024 Via Benzinga Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 September 08, 2024 From Savara Inc. Via Business Wire Savara Announces New Employment Inducement Grant September 06, 2024 From Savara Inc. Via Business Wire Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 03, 2024 From Savara Inc. Via Business Wire Savara Announces New Employment Inducement Grant August 16, 2024 From Savara Inc. Via Business Wire Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 August 15, 2024 From Savara Inc. Via Business Wire Savara Reports Second Quarter 2024 Financial Results and Provides Business Update August 12, 2024 From Savara Inc. Via Business Wire Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock June 28, 2024 From Savara Inc. Via Business Wire Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday? June 26, 2024 Via Benzinga Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
